question_id,date,category,question_text,baseline_success,baseline_actually_answered,baseline_has_expected,baseline_confidence,baseline_text,baseline_error,baseline_time,baseline_input_tokens,baseline_output_tokens,togomcp_success,togomcp_has_expected,togomcp_confidence,togomcp_text,togomcp_error,togomcp_time,togomcp_input_tokens,togomcp_output_tokens,togomcp_cache_creation_input_tokens,togomcp_cache_read_input_tokens,tools_used,tool_details,value_add,expected_answer,notes
97,2026-01-31,Structured Query,Find marketed drugs that target both kinases and have mechanism of action data available.,True,True,True,0.5,"I can help you find marketed drugs that target kinases with mechanism of action data.

Based on my training knowledge, here are some notable examples of marketed drugs that target kinases:

## Multi-Kinase Inhibitors:

1. **Sorafenib (Nexavar)** - Targets VEGFR, PDGFR, RAF kinases; used for renal cell carcinoma and hepatocellular carcinoma

2. **Sunitinib (Sutent)** - Targets multiple receptor tyrosine kinases including VEGFR and PDGFR; used for renal cell carcinoma and GIST

3. **Pazopanib (Votrient)** - Targets VEGFR, PDGFR, c-KIT; used for renal cell carcinoma and soft tissue sarcoma

4. **Regorafenib (Stivarga)** - Targets multiple kinases including VEGFR and TIE2; used for colorectal cancer and GIST

5. **Dasatinib (Sprycel)** - Targets BCR-ABL and SRC family kinases; used for chronic myeloid leukemia

6. **Ponatinib (Iclusig)** - Targets BCR-ABL and multiple other kinases; used for CML

## Selective Dual Kinase Inhibitors:

7. **Lapatinib (Tykerb)** - Targets both EGFR and HER2; used for breast cancer

8. **Afatinib (Gilotrif)** - Targets EGFR and HER2; used for non-small cell lung cancer

These drugs all have well-documented mechanisms of action involving kinase inhibition and are currently marketed for various cancer indications.",,7.391209840774536,53,425,True,True,0.5,"Excellent! I've found comprehensive information about marketed drugs that target kinases with mechanism of action data. Let me provide you with a summary:

## Marketed Drugs Targeting Kinases with Mechanism of Action Data

I found **85+ unique marketed drugs** (highestDevelopmentPhase = 4) that target kinases and have documented mechanism of action data in ChEMBL. Here are the key findings:

### Top Multi-Target Kinase Inhibitors:

1. **REGORAFENIB** (CHEMBL1946170) - 7 kinase targets
   - Targets: MAP kinase p38 beta, B-raf, RAF, ABL, FRK, TIE-2, RET
   - Mechanism: INHIBITOR

2. **BOSUTINIB** (CHEMBL288441) - 4 kinase targets
   - Targets: ABL, SRC, HCK, Lyn tyrosine kinases
   - Mechanism: INHIBITOR

3. **FILGOTINIB** - 4 kinase targets (JAK inhibitor)

4. **VANDETANIB** (CHEMBL24828) - 4 kinase targets
   - Targets: BRK, SRC, TIE-2, RET
   - Mechanism: INHIBITOR

### Drug Classes Represented:

**Tyrosine Kinase Inhibitors (TKIs):**
- **BCR-ABL inhibitors**: Imatinib, Dasatinib, Bosutinib, Nilotinib, Asciminib
- **BTK inhibitors**: Ibrutinib, Acalabrutinib, Zanubrutinib, Pirtobrutinib, Tirabrutinib
- **ALK inhibitors**: Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib
- **EGFR inhibitors**: Afatinib, Dacomitinib, Neratinib, Lapatinib, Tucatinib
- **JAK inhibitors**: Ruxolitinib, Baricitinib, Tofacitinib, Upadacitinib, Abrocitinib
- **FLT3 inhibitors**: Gilteritinib, Midostaurin, Quizartinib

**Serine/Threonine Kinase Inhibitors:**
- **MEK inhibitors**: Trametinib, Cobimetinib, Binimetinib, Selumetinib
- **RAF inhibitors**: Vemurafenib, Dabrafenib, Encorafenib
- **CDK4/6 inhibitors**: Abemaciclib, Ribociclib, Trilaciclib

**PI3K Inhibitors:**
- Idelalisib, Copanlisib, Duvelisib, Alpelisib, Umbralisib, Leniolisib

### Unique Mechanism:
- **MITAPIVAT** - Pyruvate kinase ACTIVATOR (not an inhibitor)
- **DEUCRAVACITINIB** - TYK2 NEGATIVE ALLOSTERIC MODULATOR

All these drugs have:
✓ Marketed status (development phase 4)
✓ Human protein targets
✓ Documented mechanism of action data
✓ Specific kinase targets identified

Would you like more detailed information about any specific drug class or individual compounds?",,48.840020179748535,26,2072,18455,174102,"mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__get_MIE_file"", ""input"": {""dbname"": ""chembl""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX cco: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT DISTINCT ?drugName ?targetName ?mechanismType ?chemblId\nFROM <http://rdf.ebi.ac.uk/dataset/chembl>\nWHERE {\n  ?mechanism a cco:Mechanism ;\n             cco:mechanismActionType ?mechanismType ;\n             cco:hasMolecule ?molecule ;\n             cco:hasTarget ?target .\n  ?molecule a cco:SmallMolecule ;\n            rdfs:label ?drugName ;\n            cco:chemblId ?chemblId ;\n            cco:highestDevelopmentPhase 4 .\n  ?target a cco:SingleProtein ;\n          rdfs:label ?targetName ;\n          cco:organismName \""Homo sapiens\"" .\n  ?targetName bif:contains \""'kinase'\"" option (score ?sc)\n}\nORDER BY DESC(?sc) ?drugName\nLIMIT 50""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX cco: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT DISTINCT ?drugName ?chemblId (COUNT(DISTINCT ?target) as ?targetCount) (GROUP_CONCAT(DISTINCT ?mechanismType; separator=\""; \"") as ?mechanisms)\nFROM <http://rdf.ebi.ac.uk/dataset/chembl>\nWHERE {\n  ?mechanism a cco:Mechanism ;\n             cco:mechanismActionType ?mechanismType ;\n             cco:hasMolecule ?molecule ;\n             cco:hasTarget ?target .\n  ?molecule a cco:SmallMolecule ;\n            rdfs:label ?drugName ;\n            cco:chemblId ?chemblId ;\n            cco:highestDevelopmentPhase 4 .\n  ?target a cco:SingleProtein ;\n          rdfs:label ?targetName ;\n          cco:organismName \""Homo sapiens\"" .\n  ?targetName bif:contains \""'kinase'\"" option (score ?sc)\n}\nGROUP BY ?drugName ?chemblId\nORDER BY DESC(?targetCount) ?drugName\nLIMIT 100""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX cco: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT DISTINCT ?drugName ?chemblId ?targetName ?mechanismType\nFROM <http://rdf.ebi.ac.uk/dataset/chembl>\nWHERE {\n  ?mechanism a cco:Mechanism ;\n             cco:mechanismActionType ?mechanismType ;\n             cco:hasMolecule ?molecule ;\n             cco:hasTarget ?target .\n  ?molecule a cco:SmallMolecule ;\n            rdfs:label ?drugName ;\n            cco:chemblId ?chemblId ;\n            cco:highestDevelopmentPhase 4 .\n  ?target a cco:SingleProtein ;\n          rdfs:label ?targetName ;\n          cco:organismName \""Homo sapiens\"" .\n  ?targetName bif:contains \""'kinase'\"" option (score ?sc)\n  FILTER(?drugName IN (\""IMATINIB MESYLATE\"", \""SUNITINIB\"", \""DASATINIB\"", \""REGORAFENIB\"", \""BOSUTINIB\"", \""IBRUTINIB\"", \""RUXOLITINIB PHOSPHATE\"", \""AFATINIB DIMALEATE\"", \""VANDETANIB\""))\n}\nORDER BY ?drugName ?targetName""}}]",VALUABLE,"Approved kinase inhibitors with DrugMechanism data such as IMATINIB, ERLOTINIB, SORAFENIB","COMPLEX QUERY requiring drug-target-mechanism knowledge.

Databases/Resources: ChEMBL

Knowledge Required:
- DrugMechanism entity for action type data
- Target filtering with bif:contains for 'kinase'
- highestDevelopmentPhase = 4 for marketed
- Join between molecule, target, and mechanism

Without proper knowledge: Cannot combine target text search with mechanism data.

Verified in chembl_exploration.md Pattern 5."
98,2026-01-31,Structured Query,What protein assemblies with specific oligomeric states are available in PDB?,True,True,False,0.36363636363636365,"Based on my training knowledge, the Protein Data Bank (PDB) contains numerous protein assemblies with various oligomeric states. Here are the main types you can find:

## Common Oligomeric States in PDB:

**Monomers** - Single protein chains (most basic form)

**Dimers** - Two subunits
- Homodimers (identical subunits)
- Heterodimers (different subunits)

**Trimers** - Three subunits

**Tetramers** - Four subunits (very common)
- Example: Hemoglobin (α2β2 tetramer)

**Pentamers** - Five subunits

**Hexamers** - Six subunits

**Higher-order oligomers:**
- Octamers (8 subunits)
- Decamers (10 subunits)
- Dodecamers (12 subunits)
- 24-mers, 60-mers, etc.

## Special Assembly Types:

- **Viral capsids** - Can have icosahedral symmetry with 60+ subunits
- **Proteasomes** - Large barrel-shaped complexes
- **Chaperonins** - Like GroEL (14-mer)
- **Ribosomes** - Massive ribonucleoprotein assemblies
- **Nucleosomes** - Histone octamers with DNA
- **Amyloid fibrils** - Extended polymeric assemblies

The PDB provides **biological assembly** information that describes the functionally relevant oligomeric state, which may differ from the asymmetric unit in the crystal structure.

Would you like information about specific protein families or assembly types?",,9.585592031478882,53,406,True,True,0.5454545454545454,"Perfect! The PDB contains a vast collection of protein assemblies with various oligomeric states. Here's what I found:

## Protein Assemblies with Specific Oligomeric States in PDB

The PDB contains thousands of protein structures with different oligomeric states:

### **Summary of Available Oligomeric States:**

1. **Dimers** - 98,403 entries
   - Example: Heterodimeric nitrate reductase (PDB: 1OGY)
   - Example: NF-κB p65 homodimer (PDB: 2RAM)
   - Example: HIV-1 genomic RNA dimer (PDB: 1JU1)

2. **Trimers** - 25,143 entries
   - Example: Langerin trimeric structure (PDB: 3KQG)
   - Example: GCN4 leucine zipper in trimeric state (PDB: 4DME)
   - Example: Trimeric barnase (PDB: 1YVS)

3. **Tetramers** - 32,708 entries
   - Example: Heterotetrameric sarcosine oxidase (PDB: 2GAH)
   - Example: Bacillus subtilis DegQ tetramer (PDB: 9VLH)
   - Example: Azospirillum brasilense glutamate synthase α4β4 (PDB: 6S6S)

4. **Hexamers** - 13,380 entries
   - Example: Hexameric DNA helicase RepA (PDB: 1OLO)
   - Example: Human insulin hexamer (PDB: 1AIY)
   - Example: DtpB hexamer (PDB: 8RWY)
   - Example: Hexameric barrel coiled-coil assembly (PDB: 7BAT)

5. **Octamers** - 4,948 entries
   - Example: HLA-A*0201/octameric peptide complex (PDB: 1DUY)

6. **Higher-order assemblies:**
   - **12-subunit assemblies**: TRAP protein (PDB: 3ZZL)
   - **Heptamers**: Heptameric barrel coiled-coil (PDB: 7BAW)
   - **Complex stoichiometries**: Glutamate synthase α6β6 (PDB: 6S6X), α6β4 (PDB: 6S6U)

### **Total Related to Oligomeric States:**
Over 3,661 entries specifically mentioning ""oligomeric state assembly"" in their descriptions.

The PDB database is an excellent resource for studying how proteins form quaternary structures, with dimers being the most abundant, followed by tetramers and trimers. These assemblies are crucial for protein function, regulation, and stability.",,41.277230739593506,16,1289,2977,80067,"mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity","[{""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""oligomeric state assembly"", ""limit"": 20}}, {""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""dimer"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""trimer"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""tetramer"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""hexamer"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""octamer"", ""limit"": 5}}]",CRITICAL,"Tetrameric, hexameric, and other oligomeric protein complexes including various enzymes and regulatory proteins","COMPLEX QUERY requiring assembly category knowledge.

Databases/Resources: PDB

Knowledge Required:
- pdbx_struct_assembly category for biological assembly info
- oligomeric_count and oligomeric_details properties
- struct category for entry identification
- CONTAINS filter for oligomeric state keyword

Without proper knowledge: Cannot navigate assembly metadata structure.

Verified in pdb_exploration.md Pattern 7."
99,2026-01-31,Integration,What gene functions are associated with the insulin signaling pathway?,True,True,False,0.42857142857142855,"The insulin signaling pathway involves numerous genes with diverse functions. Here are the key functional categories and associated genes:

## Core Signaling Components

**Receptor and Receptor Substrates:**
- **INSR** (insulin receptor) - transmembrane tyrosine kinase receptor
- **IRS1, IRS2, IRS3, IRS4** - insulin receptor substrates that serve as docking proteins

**PI3K-AKT Pathway (Metabolic Effects):**
- **PIK3CA, PIK3CB, PIK3CD** - catalytic subunits of PI3K
- **PIK3R1, PIK3R2** - regulatory subunits of PI3K
- **AKT1, AKT2, AKT3** - serine/threonine kinases (protein kinase B)
- **PDK1** - phosphoinositide-dependent kinase-1
- **PTEN** - negative regulator, phosphatase

**MAPK Pathway (Growth/Proliferation):**
- **GRB2, SOS1** - adaptor proteins
- **HRAS, KRAS, NRAS** - small GTPases
- **RAF1, BRAF** - MAP kinase kinase kinases
- **MAP2K1, MAP2K2** - MEK proteins
- **MAPK1, MAPK3** - ERK1/2

## Metabolic Function Genes

**Glucose Metabolism:**
- **SLC2A4 (GLUT4)** - glucose transporter
- **GSK3A, GSK3B** - glycogen synthase kinase-3
- **GYS1, GYS2** - glycogen synthases

**Lipid Metabolism:**
- **SREBF1** - sterol regulatory element-binding transcription factor
- **ACACA** - acetyl-CoA carboxylase

**Protein Synthesis:**
- **MTOR** - mechanistic target of rapamycin
- **RPS6KB1** - ribosomal protein S6 kinase

**Negative Regulators:**
- **PTPN1** - protein tyrosine phosphatase 1B
- **FOXO1, FOXO3** - forkhead box transcription factors

These genes collectively regulate glucose uptake, glycogen synthesis, protein synthesis, lipogenesis, and cell growth/survival.",,10.564792156219482,49,571,True,True,0.8571428571428571,"Based on my comprehensive search across multiple biological databases, I can provide you with detailed information about gene functions associated with the insulin signaling pathway:

## Gene Functions Associated with the Insulin Signaling Pathway

The insulin signaling pathway (GO:0008286) is defined as ""the series of molecular signals generated as a consequence of the insulin receptor binding to insulin."" This pathway is classified as a **cell surface receptor protein tyrosine kinase signaling pathway** and plays crucial roles in glucose metabolism, cell growth, and survival.

### Key Genes and Their Functions:

#### **1. Insulin Receptor (INSR/IR)**
- **UniProt ID**: P06213 (human)
- **Function**: Receptor tyrosine kinase (EC 2.7.10.1)
- **Role**: Binds insulin and initiates the signaling cascade through autophosphorylation of tyrosine residues
- **Structure**: Processed into alpha and beta subunits; the beta subunit contains the tyrosine kinase domain

#### **2. Insulin Receptor Substrates (IRS proteins)**
- **IRS1** (UniProt: P35568)
  - Functions as the primary adapter protein
  - Phosphorylated by the insulin receptor on multiple tyrosine residues
  - Creates docking sites for downstream signaling molecules
- **IRS2** - Similar function to IRS1, involved in metabolic regulation

#### **3. PI3K (Phosphatidylinositol 3-Kinase) Pathway Components**
- **PIK3CA/PIK3CB** - Catalytic subunits
  - **Function**: Lipid kinase (EC 2.7.1.137) that phosphorylates PIP2 to generate PIP3
  - **Role**: Central mediator of insulin's metabolic effects
  
#### **4. AKT/PKB (Protein Kinase B)**
- **AKT1, AKT2, AKT3**
- **Function**: Serine/threonine protein kinase
- **Role**: Key effector kinase that mediates:
  - Glucose uptake (via GLUT4 translocation)
  - Glycogen synthesis
  - Protein synthesis
  - Cell survival and proliferation

#### **5. DAF-16/FOXO Transcription Factors**
- **Function**: Transcription factors regulated by AKT phosphorylation
- **Role**: When dephosphorylated, translocate to nucleus to regulate:
  - Stress resistance
  - Longevity
  - Metabolic gene expression

### Pathway Regulation:

**Positive Regulation (GO:0046628):**
- Processes that increase insulin receptor signaling
- Includes receptor internalization for signal amplification
- Enhanced phosphorylation cascades

**Negative Regulation (GO:0046627):**
- Receptor internalization and degradation
- Protein tyrosine phosphatases
- Feedback inhibition mechanisms

### Biological Processes Controlled:

1. **Glucose Metabolism**: Glucose uptake, glycogen synthesis, gluconeogenesis inhibition
2. **Lipid Metabolism**: Lipogenesis, fatty acid synthesis
3. **Protein Synthesis**: mTOR pathway activation
4. **Cell Growth and Proliferation**: Via MAPK/ERK pathway
5. **Cell Survival**: Anti-apoptotic signaling
6. **Aging and Longevity**: Regulation of lifespan through DAF-16/FOXO

### Recent Research Findings:

According to PubMed, recent research has revealed connections between insulin signaling and other cellular processes. For example, a 2026 study ([DOI: 10.1021/acs.est.5c17589](https://doi.org/10.1021/acs.est.5c17589)) identified a mechanistic link between the insulin/IGF-1 signaling pathway and ferroptosis (iron-dependent cell death), showing that the **DAF-2-AGE-1-PDK-1-AKT-DAF-16** axis serves as a central regulatory pathway connecting metabolic signaling to cellular stress responses.

### Cross-Species Conservation:

The insulin signaling pathway is highly conserved across species:
- **Mammals** (human, mouse, rat): Complete pathway with insulin and IGF receptors
- **C. elegans**: DAF-2 (insulin/IGF receptor ortholog)
- **Drosophila**: InR (insulin receptor) and chico (IRS ortholog)

This pathway's evolutionary conservation highlights its fundamental importance in regulating metabolism, growth, and aging across diverse organisms.",,84.24534010887146,42,3044,44657,353209,"mcp__ols__search, mcp__togomcp__search_reactome_entity, mcp__ols__fetch, mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__pubmed__search_articles, mcp__togomcp__run_sparql, mcp__ols__searchClasses, mcp__togomcp__run_sparql, mcp__pubmed__get_article_metadata, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity","[{""name"": ""mcp__ols__search"", ""input"": {""query"": ""insulin signaling pathway""}}, {""name"": ""mcp__togomcp__search_reactome_entity"", ""input"": {""query"": ""insulin signaling pathway"", ""rows"": 10}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0008286""}}, {""name"": ""mcp__togomcp__get_MIE_file"", ""input"": {""dbname"": ""reactome""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""reactome"", ""sparql_query"": ""PREFIX bp: <http://www.biopax.org/release/biopax-level3.owl#>\nPREFIX xsd: <http://www.w3.org/2001/XMLSchema#>\n\nSELECT DISTINCT ?proteinName ?uniprotId ?pathwayName\nFROM <http://rdf.ebi.ac.uk/dataset/reactome>\nWHERE {\n  ?pathway a bp:Pathway ;\n           bp:displayName ?pathwayName ;\n           bp:organism ?org ;\n           bp:pathwayComponent*/bp:left|bp:right ?protein .\n  ?org bp:name \""Homo sapiens\"" .\n  ?protein a bp:Protein ;\n           bp:entityReference ?proteinRef .\n  ?proteinRef bp:name ?proteinName ;\n              bp:xref ?xref .\n  ?xref a bp:UnificationXref ;\n        bp:db \""UniProt\""^^xsd:string ;\n        bp:id ?uniprotId .\n  ?pathwayName bif:contains \""'insulin' AND 'signaling'\"" option (score ?sc)\n}\nORDER BY DESC(?sc)\nLIMIT 50""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""reactome"", ""sparql_query"": ""PREFIX bp: <http://www.biopax.org/release/biopax-level3.owl#>\n\nSELECT DISTINCT ?pathway ?pathwayName\nFROM <http://rdf.ebi.ac.uk/dataset/reactome>\nWHERE {\n  ?pathway a bp:Pathway ;\n           bp:displayName ?pathwayName .\n  ?pathwayName bif:contains \""'insulin'\"" option (score ?sc)\n}\nORDER BY DESC(?sc)\nLIMIT 20""}}, {""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""insulin signaling pathway genes molecular function"", ""max_results"": 5}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""reactome"", ""sparql_query"": ""PREFIX bp: <http://www.biopax.org/release/biopax-level3.owl#>\nPREFIX xsd: <http://www.w3.org/2001/XMLSchema#>\n\nSELECT DISTINCT ?proteinName ?uniprotId\nFROM <http://rdf.ebi.ac.uk/dataset/reactome>\nWHERE {\n  ?pathway a bp:Pathway ;\n           bp:displayName \""Insulin receptor signalling cascade\"" ;\n           bp:pathwayComponent*/bp:left|bp:right ?entity .\n  ?entity bp:entityReference ?ref .\n  ?ref bp:name ?proteinName ;\n       bp:xref ?xref .\n  ?xref a bp:UnificationXref ;\n        bp:db \""UniProt\""^^xsd:string ;\n        bp:id ?uniprotId .\n}\nLIMIT 50""}}, {""name"": ""mcp__ols__searchClasses"", ""input"": {""query"": ""insulin receptor signaling pathway"", ""ontologyId"": ""go"", ""pageSize"": 20}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""go"", ""sparql_query"": ""PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX obo: <http://purl.obolibrary.org/obo/>\n\nSELECT DISTINCT ?gene ?geneLabel ?function\nWHERE {\n  ?gene rdf:type ?type ;\n        rdfs:label ?geneLabel .\n  ?annotation rdf:type ?annotationType ;\n              ?relatesTo <http://purl.obolibrary.org/obo/GO_0008286> ;\n              ?hasGene ?gene .\n  OPTIONAL {\n    ?gene ?hasProp ?function .\n  }\n}\nLIMIT 50""}}, {""name"": ""mcp__pubmed__get_article_metadata"", ""input"": {""pmids"": [""41616222""]}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""insulin receptor"", ""limit"": 10}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""IRS1 insulin receptor substrate"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""PI3K phosphoinositide 3-kinase"", ""limit"": 5}}]",CRITICAL,GO molecular functions and biological processes related to insulin signaling,"COMPLEX QUERY requiring pathway-GO integration.

Databases/Resources: GO, MeSH (or Reactome)

Knowledge Required:
- bif:contains for 'insulin' keyword matching
- Cross-database query on primary endpoint
- Namespace filtering with STR()
- FROM clause for consistent results

Without proper knowledge: Cannot cross-reference insulin-related terms effectively.

Verified in go_exploration.md Pattern 4."
100,2026-01-31,Integration,What is the Gene Ontology term for 'apoptosis'?,True,True,False,0.3333333333333333,"The Gene Ontology term for 'apoptosis' is:

**GO:0006915 - apoptotic process**

This is the primary GO term used to describe programmed cell death or apoptosis. It falls under the Biological Process ontology.

The definition describes it as a programmed cell death process which begins when a cell receives an internal or external signal and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase, ultimately leading to cell death.

There are also many related child terms under this parent term that describe more specific aspects of apoptosis, such as:
- Regulation of apoptotic process
- Intrinsic/extrinsic apoptotic signaling pathways
- Execution phase of apoptosis
- And various tissue or cell-type specific apoptotic processes",,5.154902935028076,53,186,True,False,0.3333333333333333,"Perfect! The Gene Ontology term for apoptosis is:

**GO:0006915 - apoptotic process**

**Definition:** A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.

This is the primary Gene Ontology term used to annotate genes and gene products involved in the apoptotic process.",,26.97541093826294,18,486,10981,117464,"mcp__ols__search, mcp__ols__searchClasses, mcp__ols__fetch","[{""name"": ""mcp__ols__search"", ""input"": {""query"": ""apoptosis""}}, {""name"": ""mcp__ols__searchClasses"", ""input"": {""query"": ""apoptosis"", ""ontologyId"": ""go""}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0006915""}}]",VALUABLE,GO:0006915 (apoptotic process),"SIMPLE QUERY - Straightforward ontology lookup.

Method: OLS4 searchClasses for 'apoptosis' in GO

Demonstrates when basic ontology search tools suffice.

Verified through OLS4 search capabilities."
101,2026-01-31,Completeness,What fraction of PDB structures have associated publication records with PubMed IDs?,True,True,True,0.5,"Based on my training knowledge, the vast majority of PDB structures have associated publication records with PubMed IDs - **approximately 85-90%** of entries.

However, there are important caveats:

1. **Not all structures have publications**: Some structures are deposited without associated publications, particularly:
   - Structures from structural genomics initiatives
   - Unpublished structures
   - Structures still in preparation for publication

2. **Some publications lack PubMed IDs**: A small fraction of structures cite publications that may not be indexed in PubMed, such as:
   - Very recent preprints
   - Publications in journals not indexed by PubMed
   - Non-English language publications
   - Theses or dissertations

3. **The fraction has increased over time**: More recent PDB depositions are more likely to have associated PubMed IDs as deposition policies have become more standardized.

The exact current fraction would require querying the PDB database directly, as this is a dynamic metric that changes as new structures are deposited and publications are released. The wwPDB (Worldwide Protein Data Bank) maintains these linkages as part of their standard metadata.",,7.6962690353393555,55,267,True,True,0.75,"Perfect! Based on the SPARQL query results from the PDB RDF database, I can now provide you with the answer:

## Fraction of PDB Structures with PubMed IDs

**Results:**
- **Total PDB entries**: 245,833
- **Entries with PubMed IDs**: 169,057
- **Fraction with PubMed IDs**: **68.8%** (169,057 / 245,833)

This means that approximately **69% of PDB structures have associated publication records with PubMed IDs**. 

The remaining ~31% of structures either:
1. Were deposited without associated publications
2. Have publications that are not indexed in PubMed
3. Have publications that predate PubMed indexing
4. Are unpublished structures (structures can be deposited before publication)

It's worth noting that the MIE metadata indicated ~73% PubMed coverage, but the actual current data shows ~69%. The difference could be due to:
- The metadata statistics being from an earlier snapshot
- Some entries having citations but no PubMed IDs specifically (they may have DOIs instead)
- Data updates since the metadata was generated",,28.26580786705017,15,663,12684,91175,"mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__get_MIE_file"", ""input"": {""dbname"": ""pdb""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""PREFIX pdbx: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT \n  (COUNT(DISTINCT ?entry) as ?total_entries)\n  (COUNT(DISTINCT ?entry_with_pubmed) as ?entries_with_pubmed)\nFROM <http://rdfportal.org/dataset/pdbj>\nWHERE {\n  ?entry a pdbx:datablock .\n  \n  OPTIONAL {\n    ?entry pdbx:has_citationCategory/pdbx:has_citation ?citation .\n    ?citation pdbx:citation.pdbx_database_id_PubMed ?pubmed .\n    BIND(?entry as ?entry_with_pubmed)\n  }\n}""}}]",VALUABLE,"Approximately 69% (169,057 entries with PubMed citations out of ~245,000 total)","COMPLEX QUERY requiring citation coverage calculation.

Databases/Resources: PDB

Knowledge Required:
- citation category for publication data
- pdbx_database_id_PubMed property
- COUNT for coverage calculation
- FROM graph clause

Without proper knowledge: Cannot identify citation coverage correctly.

Verified in pdb_exploration.md Pattern 10."
102,2026-01-31,Completeness,How many UniProt cross-references exist across all PDB structures?,True,False,False,0.42857142857142855,"I don't have access to current, real-time statistics about the exact number of UniProt cross-references across all PDB structures.

However, I can tell you that:

1. **Most PDB structures have UniProt cross-references** - The vast majority of protein structures in the PDB are linked to UniProt entries, as UniProt is the primary protein sequence database.

2. **The number is in the millions** - Since there are over 200,000 structures in the PDB (as of recent years), and many structures contain multiple protein chains, each potentially having UniProt cross-references, the total number of cross-references would be substantial.

3. **One structure can have multiple cross-references** - A single PDB entry often contains multiple protein chains, and each chain typically has its own UniProt cross-reference. Additionally, some structures may reference multiple UniProt entries for the same chain (e.g., different isoforms or organisms).

For the exact current number, you would need to query the PDB database directly or check their official statistics pages, as this number changes weekly with new structure depositions.",,7.3034751415252686,52,249,True,True,0.5714285714285714,"Excellent! Now I have comprehensive information about UniProt cross-references in PDB. Let me provide you with the complete answer:

## UniProt Cross-References in PDB Structures

Based on my query of the Protein Data Bank (PDB) RDF database:

**Total UniProt cross-references: 352,114**

This includes:
- **Distinct UniProt accessions: 64,444** unique proteins
- **Total cross-reference records: 352,114** (across all PDB structures)

### Key Insights:

1. **Coverage**: The ratio of ~5.5 cross-references per unique UniProt accession indicates that many proteins have been crystallized multiple times or appear in multiple structures.

2. **High representation**: According to the PDB metadata, UniProt cross-references represent approximately **172% coverage** per PDB entry on average, which makes sense because:
   - Most structures contain multiple protein chains
   - Many structures include protein complexes with multiple UniProt entries
   - Popular proteins (like antibodies, kinases) appear in hundreds of structures

3. **Database size**: These cross-references span across approximately 204,594 PDB entries, making UniProt the most comprehensively linked external database in PDB's sequence cross-reference system.",,39.29026985168457,26,1201,13353,157372,"mcp__togomcp__run_sparql, mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX pdbo: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT (COUNT(DISTINCT ?uniprot) AS ?count)\nWHERE {\n  ?entity a pdbo:entity_polyCategory .\n  ?entity pdbo:reference_to_uniprot ?reference .\n  ?reference pdbo:has_reference_database_accession ?uniprot .\n}\n""}}, {""name"": ""mcp__togomcp__get_MIE_file"", ""input"": {""dbname"": ""pdb""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX pdbx: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT (COUNT(DISTINCT ?db_accession) AS ?uniprot_count)\nFROM <http://rdfportal.org/dataset/pdbj>\nWHERE {\n  ?entry a pdbx:datablock .\n  ?entry pdbx:has_struct_refCategory/pdbx:has_struct_ref ?ref .\n  ?ref pdbx:struct_ref.db_name \""UNP\"" ;\n       pdbx:struct_ref.pdbx_db_accession ?db_accession .\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""\nPREFIX pdbx: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\n\nSELECT (COUNT(?ref) AS ?total_uniprot_refs)\nFROM <http://rdfportal.org/dataset/pdbj>\nWHERE {\n  ?entry a pdbx:datablock .\n  ?entry pdbx:has_struct_refCategory/pdbx:has_struct_ref ?ref .\n  ?ref pdbx:struct_ref.db_name \""UNP\"" .\n}\n""}}]",CRITICAL,"352,000+ UniProt references (~1.72 per entry due to multi-chain structures)","COMPLEX QUERY requiring cross-reference aggregation.

Databases/Resources: PDB

Knowledge Required:
- struct_ref category for cross-references
- db_name = 'UNP' filter for UniProt
- COUNT aggregation
- Understanding of multi-chain structure implications

Without proper knowledge: Cannot navigate cross-reference structure.

Verified in pdb_exploration.md Pattern 2."
103,2026-01-31,Specificity,What gene types are represented in ClinVar's gene database and how do they link to NCBI Gene?,True,True,True,1.0,"Based on my training knowledge of ClinVar's structure:

## Gene Types in ClinVar

ClinVar includes several types of genes in its database:

1. **Protein-coding genes** - The most common type
2. **Non-coding RNA genes** - Including:
   - microRNAs (miRNA)
   - Long non-coding RNAs (lncRNA)
   - Small nuclear RNAs (snRNA)
   - Transfer RNAs (tRNA)
3. **Pseudogenes** - Non-functional gene copies
4. **Other gene types** - Various regulatory and structural elements

## Link to NCBI Gene

ClinVar is tightly integrated with NCBI's Gene database through:

1. **Gene IDs**: Each gene in ClinVar is linked via a unique NCBI Gene ID (also called Entrez Gene ID or GeneID), which serves as the primary identifier

2. **Cross-referencing**: Variants in ClinVar are mapped to their corresponding genes using these Gene IDs, allowing users to:
   - Navigate from variant records to comprehensive gene information
   - Access gene summaries, genomic context, and expression data
   - View all variants associated with a particular gene

3. **Data synchronization**: ClinVar uses NCBI Gene's official gene symbols, names, and annotations to maintain consistency across NCBI databases

4. **Genomic coordinates**: The relationship is maintained through genomic positions on reference assemblies (like GRCh37/GRCh38), ensuring variants are correctly associated with their genes

This integration allows ClinVar to leverage NCBI Gene's comprehensive gene information while focusing on clinical variant interpretation.",,9.289912700653076,60,378,True,True,0.7,"Based on my investigation of ClinVar's gene database and its relationship to NCBI Gene, here's what I found:

## Gene Types in ClinVar's Database

ClinVar's gene database primarily contains **one main gene type**, but it's represented through two RDF class types:

1. **`cvo:Gene`** - The ClinVar-specific gene class (~5 million triples)
2. **`med2rdf:Gene`** - The Med2RDF ontology gene class (also ~5 million triples)

Both types refer to the same gene entities - ClinVar genes are dual-typed with both classes to support interoperability.

## Gene Properties in ClinVar

The genes in ClinVar contain rich metadata with these properties (in order of prevalence):
- **Symbol** (~5M entries) - Gene symbols like ""BRCA1""
- **Genomic locations** (~2.7M) - FALDO-based coordinates
- **Gene ID** (~92K) - NCBI Gene identifiers
- **Full name** (~93K) - Complete gene names
- **Cytogenetic location** (~92K) - Chromosomal locations
- **HGNC IDs** (~28K) - Human Gene Nomenclature Committee identifiers
- **OMIM IDs** (~17K) - Online Mendelian Inheritance in Man identifiers
- **Clinical curation scores** - Triplosensitivity and haploinsufficiency (~218K each)

## How ClinVar Links to NCBI Gene

ClinVar connects to NCBI Gene through **multiple pathways**:

### 1. **Direct ID-based Linking**
- ClinVar genes have a `cvo:gene_id` property containing NCBI Gene IDs
- Example: BRCA1 has `cvo:gene_id` = 672
- The gene URI follows the pattern: `http://ncbi.nlm.nih.gov/gene/{id}`

### 2. **Variant-to-Gene Associations**
- Variants in ClinVar link to genes through a complex path:
  - `Variant` → `cvo:classified_record` → `ClassifiedRecord`
  - `ClassifiedRecord` → `sio:SIO_000628` → Gene blank node
  - Gene blank node → `med2rdf:gene` → Gene URI (`http://ncbi.nlm.nih.gov/gene/{id}`)

### 3. **TogoID Cross-Reference System**
According to TogoID, ClinVar variants can be converted to NCBI Gene IDs with the relationship:
- **Forward**: ""is located in"" (ClinVar variant → NCBI Gene)
- **Reverse**: ""has variant"" (NCBI Gene → ClinVar variant)
- Relationship ID: TIO_000062/TIO_000063

### 4. **External Cross-References**
ClinVar genes also link to:
- **HGNC** (Human Gene Nomenclature Committee) for standardized human gene symbols
- **OMIM** for Mendelian disease genes
- **UniProt** for protein products
- **Ensembl Gene** for additional genomic annotations

## Example Workflow

To trace from a ClinVar variant to NCBI Gene:
```
ClinVar Variant (VCV000856461) 
  ↓ [cvo:classified_record]
ClassifiedRecord 
  ↓ [sio:SIO_000628]
Gene Blank Node 
  ↓ [med2rdf:gene]
NCBI Gene URI (http://ncbi.nlm.nih.gov/gene/672)
  ↓ [matched with cvo:gene_id]
ClinVar Gene Entity (cvo:Gene) with symbol ""BRCA1""
```

This architecture enables seamless integration between clinical variant data (ClinVar) and comprehensive gene information (NCBI Gene), supporting clinical genomics workflows and variant interpretation.",,65.52824330329895,30,2188,60583,243965,"mcp__togomcp__ncbi_list_databases, mcp__togomcp__get_MIE_file, mcp__togomcp__togoid_getRelation, mcp__togomcp__togoid_getAllDataset, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__togoid_getAllRelation, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__ncbi_list_databases"", ""input"": {}}, {""name"": ""mcp__togomcp__get_MIE_file"", ""input"": {""dbname"": ""clinvar""}}, {""name"": ""mcp__togomcp__togoid_getRelation"", ""input"": {""source"": ""clinvar.gene"", ""target"": ""ncbigene""}}, {""name"": ""mcp__togomcp__togoid_getAllDataset"", ""input"": {}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""clinvar"", ""sparql_query"": ""PREFIX cvo: <http://purl.jp/bio/10/clinvar/>\n\nSELECT DISTINCT ?gene_type (COUNT(?gene) as ?count)\nFROM <http://rdfportal.org/dataset/clinvar>\nWHERE {\n  ?gene a cvo:Gene .\n  OPTIONAL { ?gene a ?gene_type }\n  FILTER(?gene_type != cvo:Gene)\n}\nGROUP BY ?gene_type\nORDER BY DESC(?count)""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""clinvar"", ""sparql_query"": ""PREFIX cvo: <http://purl.jp/bio/10/clinvar/>\n\nSELECT ?gene ?gene_id ?symbol ?full_name ?hgnc_id ?omim\nFROM <http://rdfportal.org/dataset/clinvar>\nWHERE {\n  ?gene a cvo:Gene ;\n        cvo:gene_id ?gene_id ;\n        cvo:symbol ?symbol .\n  OPTIONAL { ?gene cvo:full_name ?full_name }\n  OPTIONAL { ?gene cvo:hgnc_id ?hgnc_id }\n  OPTIONAL { ?gene cvo:omim ?omim }\n}\nLIMIT 20""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""clinvar"", ""sparql_query"": ""PREFIX cvo: <http://purl.jp/bio/10/clinvar/>\n\nSELECT DISTINCT ?property (COUNT(?value) as ?count)\nFROM <http://rdfportal.org/dataset/clinvar>\nWHERE {\n  ?gene a cvo:Gene .\n  ?gene ?property ?value .\n}\nGROUP BY ?property\nORDER BY DESC(?count)\nLIMIT 20""}}, {""name"": ""mcp__togomcp__togoid_getAllRelation"", ""input"": {}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""clinvar"", ""sparql_query"": ""PREFIX cvo: <http://purl.jp/bio/10/clinvar/>\nPREFIX med2rdf: <http://med2rdf.org/ontology/med2rdf#>\nPREFIX sio: <http://semanticscience.org/resource/>\n\nSELECT DISTINCT ?variant ?variant_label ?gene_uri ?gene_symbol ?gene_id\nFROM <http://rdfportal.org/dataset/clinvar>\nWHERE {\n  ?variant a cvo:VariationArchiveType ;\n           rdfs:label ?variant_label ;\n           cvo:classified_record ?classrec .\n  ?classrec sio:SIO_000628 ?gene_bn .\n  ?gene_bn med2rdf:gene ?gene_uri .\n  \n  ?gene_entity a cvo:Gene ;\n               cvo:gene_id ?gene_id ;\n               cvo:symbol ?gene_symbol .\n  \n  FILTER(?gene_symbol = \""BRCA1\"")\n}\nLIMIT 10""}}]",VALUABLE,"Gene types including protein-coding, RNA genes, pseudogenes from NCBI Gene database","COMPLEX QUERY requiring gene entity knowledge.

Databases/Resources: ClinVar, NCBI Gene

Knowledge Required:
- Cross-database join between ClinVar and NCBI Gene
- Gene type property from NCBI Gene
- BIND for URI conversion
- VALUES pre-filtering for performance

Without proper knowledge: Cannot access gene type data across databases.

Verified in clinvar_exploration.md Pattern 1."
104,2026-01-31,Specificity,Is the Rhea reaction RHEA:10000 a transport reaction?,True,False,False,0.0,"I don't have specific information about RHEA:10000 in my training data. To determine if a particular Rhea reaction is a transport reaction, I would need to look up the specific reaction details in the Rhea database.

In general, transport reactions in Rhea are those that involve the movement of molecules across membranes or between cellular compartments, rather than chemical transformations. They are typically indicated by the transfer of a compound from one location to another (e.g., ""side 1"" to ""side 2"" of a membrane) without changes to the molecular structure.

To answer your question with certainty about RHEA:10000, you would need to check the Rhea database directly or use appropriate database tools.",,5.3333351612091064,54,162,True,False,0.0,"Based on the Rhea database, **RHEA:10000 is NOT a transport reaction**.

The reaction equation is:
**pentanamide + H2O = pentanoate + NH4(+)**

This is a **hydrolysis reaction** where pentanamide (an amide) is broken down by water to produce pentanoate (a carboxylate) and ammonium ion. This is a chemical transformation reaction, not a transport reaction.

Transport reactions typically involve the movement of a molecule across a membrane without chemical modification (e.g., ""glucose [side 1] = glucose [side 2]""). In contrast, RHEA:10000 shows a clear chemical conversion where bonds are broken and formed.",,14.794822931289673,9,275,496,52655,mcp__togomcp__search_rhea_entity,"[{""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""RHEA:10000"", ""limit"": 5}}]",CRITICAL,No (isTransport = 0 for RHEA:10000),"SIMPLE QUERY - Straightforward property lookup.

Method: Direct lookup of rhea:isTransport property

Demonstrates when basic property lookups suffice.

Verified in rhea_exploration.md simple queries section."
105,2026-01-31,Currency,What software tools are most commonly used for protein structure determination and refinement?,True,True,True,0.6666666666666666,"# Common Software Tools for Protein Structure Determination and Refinement

## Structure Determination

### X-ray Crystallography
- **PHENIX** - Comprehensive suite for structure determination, refinement, and validation
- **CCP4** - Collection of programs for processing diffraction data and structure solution
- **XDS/XSCALE** - Data processing and scaling
- **HKL-2000/HKL-3000** - Data processing suite
- **SHELX** - Phasing and refinement programs
- **AutoSolve/AutoBuild** - Automated structure solution

### Cryo-EM
- **RELION** - Bayesian approach to single-particle analysis
- **cryoSPARC** - User-friendly cryo-EM processing with advanced algorithms
- **cisTEM** - User-friendly software for single-particle analysis
- **EMAN2** - Suite for single-particle reconstruction
- **CryoLo** - Deep learning-based particle picking

### NMR Spectroscopy
- **CYANA** - Automated structure calculation from NMR data
- **XPLOR-NIH** - Structure determination using experimental restraints
- **CNS** - Crystallography and NMR System

## Refinement

- **REFMAC5** (CCP4) - Maximum-likelihood refinement
- **PHENIX.refine** - Comprehensive refinement with modern methods
- **BUSTER** - Advanced refinement with TNT engine
- **COOT** - Interactive model building and refinement (graphical)
- **Crystallography & NMR System (CNS)** - Simulated annealing refinement

## Validation

- **MolProbity** - Structure quality assessment
- **PDB-REDO** - Re-refinement and validation
- **PROCHECK** - Stereochemical quality checks

Most structural biologists use combinations of these tools depending on their specific experimental method and requirements.",,10.16883111000061,52,462,True,True,0.7777777777777778,"I can provide you with information about the most commonly used software tools for protein structure determination and refinement:

## Structure Determination Methods

### X-ray Crystallography
1. **CCP4 Suite** - Comprehensive collection of programs for macromolecular crystallography
   - REFMAC5 - Refinement program
   - MOLREP - Molecular replacement
   - PHASER - Molecular replacement and phasing

2. **PHENIX** (Python-based Hierarchical ENvironment for Integrated Xtallography)
   - phenix.refine - Automated refinement
   - phenix.autobuild - Automated model building
   - Comprehensive validation tools

3. **SHELX** - Classic crystallographic software
   - SHELXD - Structure solution
   - SHELXE - Density modification and model building

4. **Coot** - Interactive model building and visualization

### Cryo-Electron Microscopy (Cryo-EM)
1. **RELION** - REgularised LIkelihood OptimisatioN
   - Particle picking and classification
   - 3D reconstruction

2. **cryoSPARC** - Fast cryo-EM structure determination
   - Ab-initio reconstruction
   - Non-uniform refinement

3. **cisTEM** - User-friendly cryo-EM processing

### NMR Spectroscopy
1. **CYANA** - Automated NOE assignment and structure calculation
2. **XPLOR-NIH** - Biomolecular structure determination
3. **ARIA** - Automated NOE assignment

## Refinement Tools

1. **REFMAC5** (CCP4) - Maximum likelihood refinement
2. **phenix.refine** - Advanced refinement with multiple restraints
3. **BUSTER** - Fast, accurate refinement
4. **CNS** (Crystallography & NMR System) - Structure determination and refinement

## Model Building & Visualization

1. **Coot** - Most popular for interactive model building
2. **PyMOL** - Molecular visualization
3. **Chimera/ChimeraX** - Visualization and analysis (especially for cryo-EM)

## Validation

1. **MolProbity** - Structure validation
2. **PROCHECK** - Stereochemical quality assessment
3. **WHATCHECK** - Structure validation
4. **PDB-REDO** - Automated re-refinement and validation

## Modern Approaches

1. **AlphaFold2** - AI-based structure prediction (not determination from experimental data, but increasingly used as a starting point)
2. **ModelAngelo** - AI-powered model building for cryo-EM maps

The choice of tools often depends on the experimental method (X-ray, cryo-EM, or NMR) and user preference. Many crystallographers use combinations like CCP4/PHENIX for refinement with Coot for manual model building.",,18.67527413368225,3,703,335,26159,,[],REDUNDANT,"PHENIX, REFMAC for refinement; SHELX, PHASER for phasing; with usage statistics","COMPLEX QUERY requiring software classification knowledge.

Databases/Resources: PDB

Knowledge Required:
- Software category traversal
- Classification filter for different stages (refinement, phasing)
- GROUP BY for usage counting
- ORDER BY for ranking

Without proper knowledge: Cannot filter by software classification.

Verified in pdb_exploration.md Pattern 5."
106,2026-01-31,Currency,What agonist drugs are available for treating metabolic disorders?,True,True,True,0.7777777777777778,"# Agonist Drugs for Metabolic Disorders

Here are the main classes of agonist drugs used in treating metabolic disorders:

## **GLP-1 Receptor Agonists** (Type 2 Diabetes & Obesity)
- **Exenatide** (Byetta, Bydureon)
- **Liraglutide** (Victoza, Saxenda)
- **Dulaglutide** (Trulicity)
- **Semaglutide** (Ozempic, Wegovy, Rybelsus)
- **Tirzepatide** (Mounjaro, Zepbound) - dual GLP-1/GIP agonist

*Effects: Increase insulin secretion, decrease glucagon, slow gastric emptying, promote weight loss*

## **PPAR Agonists** (Diabetes & Dyslipidemia)
- **Pioglitazone, Rosiglitazone** (PPAR-γ agonists/thiazolidinediones)
- **Fenofibrate, Gemfibrozil** (PPAR-α agonists/fibrates)

*Effects: Improve insulin sensitivity, affect lipid metabolism*

## **Dopamine Agonists** (Type 2 Diabetes)
- **Bromocriptine** (Cycloset)

*Effects: Modulates hypothalamic regulation of metabolism*

## **Thyroid Hormone Agonists**
- **Levothyroxine** (hypothyroidism)
- Selective thyroid hormone receptor-β agonists are in development

## **FXR Agonists** (Under Investigation)
- For NASH and metabolic dysfunction

These medications work through various mechanisms to improve glucose control, insulin sensitivity, lipid profiles, and body weight in patients with metabolic disorders.",,8.369919061660767,50,445,True,True,0.8888888888888888,"Based on the latest research from PubMed and database searches, here's a comprehensive overview of agonist drugs available for treating metabolic disorders:

## **Major Classes of Agonist Drugs for Metabolic Disorders**

### **1. GLP-1 Receptor Agonists (Glucagon-Like Peptide-1)**
These are among the most transformative medications for metabolic disorders, particularly type 2 diabetes and obesity:

**Available drugs include:**
- **Semaglutide** (Ozempic, Wegovy) - Weekly injection
- **Liraglutide** (Victoza, Saxenda) - Daily injection
- **Dulaglutide** (Trulicity) - Weekly injection
- **Exenatide** (Byetta, Bydureon) - Twice daily or weekly

**Benefits:**
- Excellent glycemic control in type 2 diabetes
- Significant weight loss (5-15% body weight reduction)
- Low risk of hypoglycemia
- Cardiovascular protection (reduced risk of heart attack, stroke, cardiovascular death)
- Kidney protection (reduced albuminuria, slower decline in kidney function)
- According to recent research, [liraglutide may even reduce intestinal obstruction risk](https://doi.org/10.3390/ijms27020608)

### **2. Dual GIP/GLP-1 Receptor Agonists**
**Tirzepatide** (Mounjaro, Zepbound) is the most notable:
- Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors
- [Shows superior efficacy compared to single receptor agonists](https://doi.org/10.1007/s13679-025-00681-5) for:
  - Greater weight loss (up to 20-25% body weight)
  - Better glycemic control
  - Improved body composition (reduced visceral fat)
  - Benefits for heart failure with preserved ejection fraction
  - Improvements in fatty liver disease
  - Symptomatic relief in obstructive sleep apnea and knee osteoarthritis

### **3. PPAR Agonists (Peroxisome Proliferator-Activated Receptor)**
These improve insulin sensitivity:
- **Pioglitazone** (Actos) - PPAR-gamma agonist for type 2 diabetes
- **Rosiglitazone** (Avandia) - Less commonly used due to cardiovascular concerns
- Benefits: Improved insulin sensitivity, reduced inflammation, may help with fatty liver disease

### **4. SGLT2 Inhibitors (Sodium-Glucose Cotransporter 2)**
While technically not ""agonists,"" they work synergistically with agonist therapies:
- Examples: Canagliflozin, Dapagliflozin, Empagliflozin
- [Often used in combination with GLP-1 agonists for ""diabesity""](https://doi.org/10.1007/s13679-025-00681-5)

## **Emerging Therapies**

According to [recent research](https://doi.org/10.1016/S0140-6736(25)02105-1), next-generation medications in development include:

1. **Triple receptor agonists** (GIP-GLP-1-Glucagon) - Promise even greater weight loss efficacy
2. **Dual GLP-1/Glucagon agonists** - Enhanced metabolic benefits
3. **Dual GLP-1/Amylin agonists** - Additional appetite suppression
4. **Small-molecule oral GLP-1 agonists** - For improved convenience and adherence

## **Clinical Applications**

These agonist drugs are approved or being studied for:
- **Type 2 diabetes** - Primary indication
- **Obesity** - Major new indication
- **Cardiovascular disease prevention** - Proven benefits
- **Chronic kidney disease** - Slows progression
- **Fatty liver disease (MASLD/MASH)** - Regression of steatosis and fibrosis
- **Heart failure with preserved ejection fraction**
- **Potential future uses**: Neurodegenerative diseases, substance use disorders

## **Important Considerations**

- **Side effects**: Common gastrointestinal effects include nausea, vomiting, loss of appetite, and abdominal pain
- **Contraindications**: Pregnancy, lactation, pediatric use (in some cases), certain kidney conditions
- **Dosing**: Gradual dose escalation is essential to minimize side effects
- **Access**: [Public awareness is growing, particularly through social media](https://doi.org/10.1097/MD.0000000000046957), though cost and insurance coverage remain barriers

These medications represent a paradigm shift in treating metabolic disorders by addressing multiple interconnected problems—glucose metabolism, obesity, cardiovascular risk, and kidney function—through complementary mechanisms of action.",,42.55797290802002,17,1659,10883,79999,"mcp__pubmed__search_articles, mcp__chembl__search_chembl_molecule, mcp__chembl__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__pubmed__get_article_metadata","[{""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""agonist drugs metabolic disorders treatment"", ""max_results"": 30}}, {""name"": ""mcp__chembl__search_chembl_molecule"", ""input"": {""query"": ""GLP-1 agonist"", ""limit"": ""10""}}, {""name"": ""mcp__chembl__search_chembl_molecule"", ""input"": {""query"": ""PPAR agonist"", ""limit"": ""10""}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""semaglutide"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""pioglitazone"", ""limit"": 5}}, {""name"": ""mcp__pubmed__get_article_metadata"", ""input"": {""pmids"": [""41596262"", ""41583490"", ""41547366"", ""41528611"", ""41517730""]}}]",VALUABLE,Agonist drugs for metabolic conditions including GLP-1 receptor agonists for diabetes,"COMPLEX QUERY requiring mechanism-indication integration.

Databases/Resources: ChEMBL

Knowledge Required:
- DrugMechanism entity for action type
- mechanismActionType = 'AGONIST' filter
- DrugIndication for metabolic disease filtering
- Cross-entity joins

Without proper knowledge: Cannot combine mechanism type with indication data.

Verified in chembl_exploration.md Pattern 5."
107,2026-01-31,Precision,What is the activity type distribution for bioactivity measurements in ChEMBL?,True,False,False,0.4444444444444444,"I don't have access to real-time ChEMBL database statistics in my training data, but I can provide you with general information about the typical activity type distribution found in ChEMBL.

ChEMBL contains millions of bioactivity measurements, and the most common activity types typically include:

**Most Frequent Activity Types:**

1. **IC50** (Half-maximal Inhibitory Concentration) - Usually the most abundant, representing ~30-40% of all measurements
2. **Ki** (Inhibition constant) - Often the second most common, ~10-20%
3. **EC50** (Half-maximal Effective Concentration) - ~5-10%
4. **Potency** - General potency measurements, ~5-10%
5. **Activity** - General activity measurements, ~3-5%
6. **Kd** (Dissociation constant) - ~2-5%
7. **%Inhibition** - Percentage inhibition at a specific concentration, ~2-5%

**Other Common Types:**
- MIC (Minimum Inhibitory Concentration)
- GI50 (50% Growth Inhibition)
- ED50 (Median Effective Dose)
- LC50 (Median Lethal Concentration)
- Various other specialized measurements

The exact distribution can vary significantly depending on:
- The ChEMBL version
- Target class (kinases vs GPCRs vs other proteins)
- Therapeutic area
- Time period of data collection

For current, precise statistics, you would need to query the ChEMBL database directly or check their latest release documentation.",,8.705697059631348,55,377,True,False,0.4444444444444444,"Excellent! Here's the **activity type distribution for bioactivity measurements in ChEMBL**:

## Summary Statistics
- **Total bioactivity measurements**: 21,123,501 (out of ~20M reported in documentation)
- **Top 50 activity types** shown below

## Top Activity Types

| Rank | Activity Type | Count | Percentage |
|------|--------------|--------|-----------|
| 1 | **Potency** | 4,473,542 | 21.2% |
| 2 | **IC50** | 2,802,898 | 13.3% |
| 3 | **GI50** | 2,623,650 | 12.4% |
| 4 | **Inhibition** | 1,532,464 | 7.3% |
| 5 | **Percent Effect** | 1,328,366 | 6.3% |
| 6 | **Activity** | 1,281,656 | 6.1% |
| 7 | **Ki** | 775,444 | 3.7% |
| 8 | **MIC** | 748,009 | 3.5% |
| 9 | **EC50** | 522,752 | 2.5% |
| 10 | **INHIBITION** | 339,133 | 1.6% |

## Key Findings

**Most Common Activity Types:**
1. **Potency** (21.2%) - General measure of biological activity
2. **IC50** (13.3%) - Half maximal inhibitory concentration
3. **GI50** (12.4%) - Growth inhibition 50% (cancer research)
4. **Inhibition** (7.3%) - Percentage inhibition measurements
5. **Percent Effect** (6.3%) - General efficacy measurements

**Major Categories:**
- **Binding affinity**: IC50, Ki, Kd, EC50 (~20% combined)
- **Cell viability**: GI50, CC50, LC50, TGI (~13%)
- **Antimicrobial**: MIC, MIC50, MIC90 (~3.8%)
- **Pharmacokinetics**: CL, AUC, Cmax, T1/2, F (~1.3%)
- **Solubility & Stability**: LogD, Solubility, Stability (~0.5%)

The distribution shows that ChEMBL contains diverse bioactivity data covering drug discovery (IC50, Ki), cell-based assays (GI50, Inhibition), antimicrobial testing (MIC), and ADME properties (pharmacokinetic parameters).",,37.552775144577026,21,1134,12825,129411,"mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__get_MIE_file"", ""input"": {""dbname"": ""chembl""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX cco: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT ?activityType (COUNT(?activity) AS ?count)\nFROM <http://rdf.ebi.ac.uk/dataset/chembl>\nWHERE {\n  ?activity a cco:Activity ;\n            cco:standardType ?activityType .\n}\nGROUP BY ?activityType\nORDER BY DESC(?count)\nLIMIT 50""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX cco: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT (COUNT(?activity) AS ?totalActivities)\nFROM <http://rdf.ebi.ac.uk/dataset/chembl>\nWHERE {\n  ?activity a cco:Activity ;\n            cco:standardType ?activityType .\n}""}}]",CRITICAL,"Potency (4.4M), IC50 (2.8M), GI50 (2.6M), Inhibition (1.5M), Ki (775K)","SIMPLE QUERY - Straightforward activity type count.

Method: GROUP BY on activity type with COUNT

Demonstrates straightforward aggregation queries.

Verified in chembl_exploration.md simple queries section."
108,2026-01-31,Precision,What is the UniProt ID for the CRISPR-associated protein Cas9 from Streptococcus pyogenes?,True,True,True,1.0,"The UniProt ID for the CRISPR-associated protein Cas9 from Streptococcus pyogenes is **Q99ZW2**.

This is the most commonly referenced Cas9 protein, specifically from Streptococcus pyogenes serotype M1 strain SF370. This particular Cas9 variant is widely used in genome editing applications and is often referred to as SpCas9.",,3.4109597206115723,68,97,True,True,1.0,"The **UniProt ID for CRISPR-associated protein Cas9 from Streptococcus pyogenes** is **Q99ZW2**.

This entry corresponds to:
- **Protein name**: CRISPR-associated endonuclease Cas9/Csn1 (EC 3.1.-.-)
- **Common names**: SpCas9, SpyCas9
- **Organism**: Streptococcus pyogenes serotype M1

This is the most well-characterized and widely used Cas9 protein in genome editing applications. There are several other UniProt entries for Cas9 from different S. pyogenes strains, but Q99ZW2 is the canonical reference entry for the serotype M1 strain, which is the most commonly used variant in CRISPR-Cas9 technology.",,15.872411966323853,9,320,1032,52669,mcp__togomcp__search_uniprot_entity,"[{""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""Cas9 Streptococcus pyogenes"", ""limit"": 10}}]",VALUABLE,Q99ZW2,"SIMPLE QUERY - Straightforward protein lookup.

Method: search_uniprot_entity('Cas9 Streptococcus pyogenes')

Demonstrates when basic protein search tools suffice.

Verified in example_questions.json question 1."
